![Page 1: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates](https://reader034.vdocument.in/reader034/viewer/2022042404/5f1a5aed11580123e717e198/html5/thumbnails/1.jpg)
STARTUP X 1
Mentoring for Startups
ReviveMedUnlocking the Value of Metabolomics
Leila Pirhaji, Ph.D.Founder and CEO
![Page 2: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates](https://reader034.vdocument.in/reader034/viewer/2022042404/5f1a5aed11580123e717e198/html5/thumbnails/2.jpg)
Presentation Overview
• ReviveMed’s Summary
• My Journey
• The role of my mentors in my journey
![Page 3: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates](https://reader034.vdocument.in/reader034/viewer/2022042404/5f1a5aed11580123e717e198/html5/thumbnails/3.jpg)
New Use of Existing Drugs Could Save Millions of Lives
Non-Alcoholic Fatty Liver has no Treatments
10,000s of Existing Drugs,>$1 Trillion of R&D
![Page 4: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates](https://reader034.vdocument.in/reader034/viewer/2022042404/5f1a5aed11580123e717e198/html5/thumbnails/4.jpg)
ReviveMed Solves the Puzzle Using Metabolomics
Existing AI/Machine-LearningLast decade
Metabolites>40,000 Small Molecules
ProteinDNA RNA
ReviveMedNow!
![Page 5: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates](https://reader034.vdocument.in/reader034/viewer/2022042404/5f1a5aed11580123e717e198/html5/thumbnails/5.jpg)
ReviveMed’s Pioneering Machine-Learning Algorithm
Developed at MIT Our patent-pending technology
was published at:
![Page 6: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates](https://reader034.vdocument.in/reader034/viewer/2022042404/5f1a5aed11580123e717e198/html5/thumbnails/6.jpg)
Because of tremendous diversity of metabolites, current platforms can only detect 500-700 of them (<5%)
Metabolomics had been Underutilized, Until Now!
![Page 7: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates](https://reader034.vdocument.in/reader034/viewer/2022042404/5f1a5aed11580123e717e198/html5/thumbnails/7.jpg)
ReviveMed Enables Leveraging Metabolomics
Reduces the need for costly and slow processes to identify large-set of metabolites
Proprietary Database Machine-
Learning
![Page 8: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates](https://reader034.vdocument.in/reader034/viewer/2022042404/5f1a5aed11580123e717e198/html5/thumbnails/8.jpg)
ReviveMed Revolutionizes Discovering New Treatments
Therapeutic Insights
Pre-clinically validatedReviveMed
Tissue Serum
Hospitals/Disease Associations
CROs
Whitehead/Harvard Metabolomic Facilities
I. Disease PathwaysII. Therapeutic TargetsIII. Existing (pre-, post-, no-
patent) drug CandidatesIV. Serum Biomarkers
Saving 100s of Millions and Years from Discovery to Clinic
![Page 9: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates](https://reader034.vdocument.in/reader034/viewer/2022042404/5f1a5aed11580123e717e198/html5/thumbnails/9.jpg)
ReviveMed Creates Value for Patients and Pharma
$55 B
Market Opportunity
Technology FitUniquely leveraging data
from 1000s of metabolites
The Next Breakout
Biotech Market
Market Size> 60M Americans
>$35B by 2025
ReviveMed Platform
Therapeutics for metabolic diseases
1st Therapeutic Focus
Therapeutics for non-alcoholic fatty liver
![Page 10: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates](https://reader034.vdocument.in/reader034/viewer/2022042404/5f1a5aed11580123e717e198/html5/thumbnails/10.jpg)
It wouldn’t be possible without Boston's Biotech Ecosystem
Boston’s Biotech
Ecosystem
Mentors
Academic research
Investment capital
Talent
Government
Industry
![Page 11: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates](https://reader034.vdocument.in/reader034/viewer/2022042404/5f1a5aed11580123e717e198/html5/thumbnails/11.jpg)
Boston is the Hollywood for Biotech Entrepreneurs
Legendary Stars Legendary Startups
![Page 12: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates](https://reader034.vdocument.in/reader034/viewer/2022042404/5f1a5aed11580123e717e198/html5/thumbnails/12.jpg)
My Entrepreneurial Journey – Academic Phase
Catching the entrepreneurial virus
Learning entrepreneurship
Practicing entrepreneurship
![Page 13: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates](https://reader034.vdocument.in/reader034/viewer/2022042404/5f1a5aed11580123e717e198/html5/thumbnails/13.jpg)
My Entrepreneurial Journey – Beyond Academia
![Page 14: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates](https://reader034.vdocument.in/reader034/viewer/2022042404/5f1a5aed11580123e717e198/html5/thumbnails/14.jpg)
Most Important Part of these Programs are Mentorships
![Page 15: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates](https://reader034.vdocument.in/reader034/viewer/2022042404/5f1a5aed11580123e717e198/html5/thumbnails/15.jpg)
Always Seeking for Mentors
![Page 16: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates](https://reader034.vdocument.in/reader034/viewer/2022042404/5f1a5aed11580123e717e198/html5/thumbnails/16.jpg)
The Power of Mentorships
![Page 17: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates](https://reader034.vdocument.in/reader034/viewer/2022042404/5f1a5aed11580123e717e198/html5/thumbnails/17.jpg)
Leveraging Mentors’ Professional Network
![Page 18: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates](https://reader034.vdocument.in/reader034/viewer/2022042404/5f1a5aed11580123e717e198/html5/thumbnails/18.jpg)
Foster Mentorship
![Page 19: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates](https://reader034.vdocument.in/reader034/viewer/2022042404/5f1a5aed11580123e717e198/html5/thumbnails/19.jpg)
Moving Beyond Mentor-Mentee Relationships
![Page 20: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates](https://reader034.vdocument.in/reader034/viewer/2022042404/5f1a5aed11580123e717e198/html5/thumbnails/20.jpg)
ReviveMed’s World-Class Team & Advisors
Prof. Ernest FraenkelCo-founder & Board
Member
Associate Professor of at MIT
Dr. Andrey Zarur
Board Member
CEO at GreenLightBiosciences
Lecturer at MIT Sloan
Prof. Clary ClishScientific Advisor
Director of Metabolomics Broad Institute
Prof. Matthew Vander Heiden
Scientific advisor
Associate Professor of Biology at MIT
Scientific advisor
Director of Data Sciences Fortune 500 Pharma
No public disclosures
Leila Pirhaji, Ph.D.Founder & CEO
Inventor of the technologyPhD in Bioengineering at MIT
![Page 21: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates](https://reader034.vdocument.in/reader034/viewer/2022042404/5f1a5aed11580123e717e198/html5/thumbnails/21.jpg)
ReviveMed: An Award-Winning Start-Up Company>$50 K in Cash Prize $50 K of Lab Space $200 K in Cloud Computing Credits
Machine-learning CompetitionTop 10 finalists
Analytic PrizeTop 26 Winners of 2017
![Page 22: Mentoring for Startups ReviveMed · CROs Whitehead/Harvard Metabolomic Facilities I. Disease Pathways II. Therapeutic Targets III. Existing (pre-, post-, no-patent) drug Candidates](https://reader034.vdocument.in/reader034/viewer/2022042404/5f1a5aed11580123e717e198/html5/thumbnails/22.jpg)
22
www.revive-med.com
617.955.6425
@Revive_Med
ReviveMedTransforming Metabolomics Data into
the Right Therapeutics for the Right Patients